Breaking News, Financial News

Financial Report: Abraxis BioScience

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abraxis BioScience, Inc. 2Q Revenue: $242.5 million (+51%) 2Q Earnings: $23.1 (loss of $90.8 million 2Q2006) YTD Revenues: $454.7 million (+49%) YTD Earnings: $34.2 (loss of $88.9 million YTD2006) Comments: In the quarter, Abraxane revenue was up 116.7% to $78.7 million. The company recently announced plans to separate its proprietary business, Abraxis Oncology and Abraxis Research (ABI), from its hospital-based business, Abraxis Pharmaceutical Products (APP). Until the separ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters